Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-03-01
2001-10-16
Goldberg, Jerome D. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06303596
ABSTRACT:
BACKGROUND OF THE INVENTION
Cell death proceeds by one of two mechanisms: necrosis or apoptosis. In necrosis, the cells lyse and cytosolic components are released. The released cytosolic components elicit severe inflammatory responses. Apoptosis does not result in the release of cytosolic contents, as the cell membrane remains intact even though its surface properties may change. Apoptosis may include the break up of cells into apoptotic bodies, spherical pieces of cells in which the membrane still prevents the release of cytosolic contents. Apoptotic cells and apoptotic bodies are removed in the body by phagocytic cells which are believed to recognize the need to remove such cells by the changes in the outer leaflet of the membrane, in which phosphatidylserine is exposed. Apoptosis typically does not provoke inflammatory responses the way necrosis does because in the former case, the cells are removed by phagocytosis before the cytosolic content is released.
Although cells undergoing apoptosis in vitro initially have intact cell membranes, cells in advanced stages of apoptosis can exhibit loss of membrane integrity. This process is sometimes called “secondary necrosis.” It can be observed owing to the absence of phagocytic cells, which in vivo would have removed the apoptotic cells and cell fragments before they could become necrotic.
When neoplastic (tumor) cells are present in the body, it is desirable to cause the death of such cells without causing the death of the normal cells which the patient needs to sustain his life. It is desirable to cause the death of neoplastic cells by inducing apoptosis, so that the cytosolic contents of the neoplastic cells are not released.
Antineoplastic drugs have been reported which kill tumor cells by inducing apoptosis. While some of these drugs have been successful in treating some types of cancer, the drugs have also been known to induce severe side effects, such as cytotoxicity to normal cells by interference with basic cellular functions such as protein synthesis or DNA replication. A few inducers of apoptosis in monocytes have been reported. For example, human blood monocytes can undergo apoptosis when cultured in the absence of serum or stimulatory factors (which is impossible to achieve in vivo). Mangan, et al., “Lipopolysaccharide, tumor necrosis factor-&agr;, and IL-1&bgr; prevent programmed cell death (apoptosis) in human peripheral blood monocytes,”
J Immunol
146:1541 (1991). This process takes two to three days for approximately 50% of the monocytes to become apoptotic (Mangan, et al., “IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes,”
J Immunol
148:1812 (1992)), and apoptosis can be postponed by lipopolysaccharide (LPS), interleukin (IL)-1, and &agr;-tumor necrosis factor (TNF&agr;). In addition, the anti-inflammatory cytokine IL-4 can enhance apoptosis in LPS-stimulated monocytes. Mangan, D. F. and Wahl, S. M., “Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines,”
J Immunol
147:3408-3412(1991). Apoptosis has also been induced in several different cell types by the use of a number of cytokines. However, the potential use of cytokines for treatment of cancer in vivo has suffered from drawbacks, since they have been reported to elicit a variety of deleterious effects, including shock, circulatory collapse and death. In addition, the manufacture of cytokines has been to date, complicated and expensive since recombinant technology for manufacturing proteins is not an inexpensive proposition on a large scale basis.
Further adding to the complicated nature of leukemia treatment is the fact that there are many different types of leukemia. In viewing the scheme of hemopoiesis, pluripotent stem cells divide to form either lymphoid stem cells or myeloid stem cells. Lymphocytes are produced from lymphoid stem cells, while monocytes and granulocytes such as neutrophils, eosinophils and basophils are produced from myeloid stem cells. Myeloid stem cells also give rise to erythrocytes and megakaryocytes. Various leukemias resulting from these differentiated cells include lymphocytic leukemia, monocytic leukemia, and myeloid leukemia. Treatment methodologies and prognosis differ depending on the specific type of leukemia.
Particularly difficult to treat are myeloid and monocytic leukemias. Current treatment methods have achieved palliation and not cure. For example, patients having monocytic leukemia are generally thought to have a low cure rate of less than ten percent. A true remission is impossible to achieve because the Ph-positive clone persists in the bone marrow, and intense chemotherapy treatments designed to eliminate or reduce the clone have only provided modest improvements in the length of survival of these patients. Current chemotherapy is designed to keep the patient asymptomatic for long periods of time by maintaining a total white blood count within an acceptable range.
It is, therefore, desirable to find a new agent that could selectively cause apoptosis of monocytic, myeloid, and leukemia cells without causing severe side effects that accompany the administration of traditional chemotherapeutic agents. It has now been found that a known composition, taurolidine, can be used for the induction of apoptosis in monocytic and myeloid cells.
REFERENCES:
patent: 5593665 (1997-01-01), Pfirrmann et al.
Arends, M.J. and Wyllie, A.H., “Apoptosis: mechanisms and roles in pathology,”Int Rev Exp Path32:223-254 (1991).
Bauer, et al., “Tissue factor gene expression in acute myeloblastic leukemia,”Thromb Res56:425-430 (1989).
Bedrosian, et al., “Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells,”Cytokine3:568-575 (1991).
Billing, A., et al., “The influence of taurolin on defense functions and bacterial growth in human peritonitis,”Langenbecks Arch. Chir.377:180-185 (1992).
Boyle, et al., “Apoptosis in C3H-10T1/2 cells: role of intracellular pH, protein kinase C, and the Na+/H+ antiporter,”J. Cell Biochem67:231-240 (1997).
Browne, M.K., “Staphylococcus septicaemiacase report,” InTaurolin, Ein Neues Konzept zur Antimikrobiellen Chemotherpie Chirurgischer Infektionen,Bruchner, W.L. and Pfirrmann, R.W. (eds), Muchen—61-63. Wein-Baltimore, Urban & Schwarzenberg, p. 61-63, 1985.
Browne, M.K., et al., “A controlled trial of taurolin in established bacterial peritonitis,”Surg Gynecol Obstet146:721-724 (1978).
Browne, M.K., “Pharmacological and clinical studies with taurolin.” InTaurolin, Ein Neues Konzept zur Antimikrobiellen Chemotherpie Chirurgischer Infektionen,Bruchner, W.L. and Pfirrmann, R.W. (eds), Muchen-Wein-Baltimore, Urban & Schwarzenberg, p.51-60, 1985.
Browne, M.K., et al., “Taurolin, a new chemotherapeutic agent,”J. Appl. Bacter.41:363-368 (1976).
Chand, N., et al., “Disease modifying activity to taurolin in adjuvant-induced arthritis in rats,”Pharmacologist,34(3):205; abstract #376 (1992).
Darzynkiewicz, et al., “Assays of cell viability: discrimination of cells dying by apoptosis,”Methods Cell Biol41:15-38 (1994).
Dofferhoff, et al., “The release of endotoxin from antibiotic-treatedEscherichia coliand the producion of tumour necrosis factor by human monocytes,”J Antimicrob Chemother31:373-384 (1991).
Evans, et al., “Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells,” Cancer Res 53:1735-1738 (1993).
Gansauge, et al., “The induction of apoptosis in proliferating human fibroblasts by oxygen radicals is associated with a p53- and p21WAF1CIP1induction,” FEBS Letters 404:6-10 (1997).
Gavriali, et al., “Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation,”J Cell Biol119:493-501 (1992).
Gorman, et al., “Reduced adherence of microorganisms to human mucosal epithelial cells following treatment with taurolin, a novel antimicrobial agent,”J Appl Bacteriol62:315-320 (1987).
Gregory, et al., “Regulat
Hamik Anne
Morrissey James H.
Clarke Kevin B.
Goldberg Jerome D.
Oklahoma Medical Research Foundation
LandOfFree
Use of taurolidine for treatment of leukemias does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of taurolidine for treatment of leukemias, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of taurolidine for treatment of leukemias will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2596868